Search ARM

Ensoma is expanding the reach of the curative power of precision genomic medicine by pioneering an off-the shelf and portable in vivo approach using its Engenious vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g. chemotherapy) directly to hematopoietic stem cells (HSCs) or the various cell types that arise from these cells, such as T cells, B cells and myeloid cells. As a result, Ensoma’s therapies can be delivered for both rare and common diseases as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited. Ensoma launched with a $70 million Series A financing led by co-founder and seed investor 5AM Ventures, with participation from F-Prime Capital, Takeda Ventures, Viking Global Investors, Cormorant Asset Management, RIT Capital Partners, Symbiosis II, LLC, and Alexandria Venture Investments as well as a strategic collaboration with Takeda. For more information, visit

Contact Ensoma
Visit Website